Alpha Healthcare III (NASDAQ:ALPA) announced this morning that it has signed a non-binding LOI for its combination Carmell Therapeutics to acquire an unnamed commercial-stage biotech firm for about $65 million.
The consideration would come in the form of $8 million in cash and $57 million in combined Carmell stock at close plus $75 million in potential milestone payments paid out along the same split (12% cash and 88% shares). This target company’s shares would be locked for 12 months following close.
The $140 million total potential value of this acquisition comes close to doubling the scale of the initial combination with Carmell, which was struck at $188 million enterprise value. Pittsburgh-based Carmell is developing a treatment platform to accelerate healing in bone fractures and soft tissue wounds.
It could also provide Carmell with some cash flow nearer at hand post-close as the target generated about $5 million in EBITDA from $50 million in revenue during the 12 months ending March 31, 2023.
The target also has a sales contract in place with a purchasing organization with coverage in about 1,500 US hospitals. Carmell’s therapies on the other hand remain at the clinical stage with its most advanced candidates undergoing Phase II trials.
This acquisition agreement remains non-binding, however, and may not come to fruition. In the meantime, it may serve as an amuse-bouche for Alpha Healthcare III investors as they head into a completion vote for the Carmell deal on July 11.
Terms Tracker for the Week Ending October 11, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This week was sandwiched in between the Rosh Hashanah and Yom Kippur holidays, and as such, it was on the lighter side for news. In...
Much has been written about the rise and fall of companies from the last SPAC cycle. But, the turning tides of the past month would seem to suggest that perhaps more than a SPAC-specific trend, what the market saw was mostly macro factors all along. In the aggregate, the 199 companies that listed via DeSPAC...
At the SPAC of Dawn October is quickly catching up to last month’s SPAC IPO figures and is now pacing to break them with two more SPACs pricing last night. This comes amid continued signals that the IPOs of all kinds are not keeping up with rising market sentiment and a high demand for private...
Rising Dragon Acquisition Corp. announced the pricing of its $50 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “RDACU”, Friday, October 11, 2024. The new SPAC does not plan to target a particular industry or geography in its combination search but plans to leverage the experience of...
Cohen Circle Acquisition Corp. I announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIRU”, Friday, October 11, 2024. The Company’s primary focus will be to identify companies in the financial services technology (fintech) sector and fintech adjacent sectors that power transformation...